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1. Introduction 
The largest body of evidence involving the use of hyperbaric oxygen for neurologic illness is 
found in the field of cerebral ischemia. At the center of an infarct, blood flow is completely 
absent, causing neurons to die within a matter of minutes. This area, therefore, may not be 
amenable to treatment after the start of symptoms.  The region of the brain that draws the 
most interest is the penumbra, where evidence has shown that blood flow is diminished, but 
not absent. The cells in this region remain viable for a prolonged period, and can be saved if 
adequate perfusion is restored. The only FDA approved therapies for acute ischemic stroke 
include tPA, and interventional intra-arterial treatments aimed at restoring blood flow to the 
ischemic penumbra, but must be used within the first few hours of the onset of symptoms. 
There is also evidence that a percentage of the cells subjected to prolonged ischemia will 
inevitably undergo apoptosis, either after prolonged ischemia or due to reperfusion injury 
in the case of temporary ischemia. As a result, there has been great interest in using HBO2T 
for the added benefit of its anti-inflammatory and anti-apoptotic properties. There is 
reasonable evidence from animal studies, involving mice, rats, gerbils, and cats that damage 
from focal cerebral ischemia is ameliorated after treatment with HBO2T. Several human 
trials investigating the use of HBO2T for ischemic stroke have also been performed. Most of 
these lacked controls, as well as uniform standards for inclusion criteria and outcome 
measurement. There have been three prominent randomized controlled studies that have 
evaluated HBO2T in ischemic stroke, none of which where able to demonstrate statistically 
significant benefit. One might conclude from this that HBO2T is an ineffective treatment for 
ischemic stroke, however, it should be noted that these studies enrolled patients well after 
the therapeutic window of 6 - 12 hours suggested by previous animal studies. Additionally, 
two of the three also used lower doses of HBO2T than was found effective in animal studies. 
Based on our present understanding of ischemia, one would not expect improvement in 
measured outcomes under these conditions.  
It seems therefore reasonable to assess patients presenting for potential HBO2T for a pattern 
of penumbra as this provides the strongest evidence of recoverable tissue. As the ischemic 
penumbra represents the area which is expected to be most salvageable, it is reasonable to 
determine whether a penumbra is or is not present in patients undergoing experimental 
treatment with HBO2T. On MRI, penumbra is represented by perfusion-diffusion mismatch. 
More simply stated, we must find the area of brain which is dying in hope that HBO2.T can 
still save it before it is dead. This is called ischemic penumbra. In the rat model of focal 
ischemic stroke produced via thrombotic occlusion of the MCA, MRI revealed perfusion-
diffusion mismatch which persists up to 6-12 hours after the occlusion. In patients such 
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mismatch is usually present during the first 6 hours after stroke.  Noticeably, HBO2T was 
effective against experimental stroke if administered when a penumbra is typically present 
in the brain.  HBO2T administered at a time when penumbra is usually gone (e.g. at 23 
hours) may even be harmful. The clinical trials done with HBO2T so far did not follow this 
paradigm, which creates the most important discrepancy between experimental and clinical 
work. We propose that the evaluation of patients in any future clinical trial should include 
separate subgroup analyses of patients with and without confirmed penumbra as the impact 
on outcomes may be different in these two groups. 
As the accepted standards of stroke care are paramount in treatment of any patient 
presenting with acute stroke,  patients presenting within the therapeutic window for tPA 
should be treated with tPA but should be considered for HBO2T  as well if they have 
persistent neurologic deficits on physical examination and can be treated within the time 
window.  This is because even in cases of temporary ischemia HBO2T has shown benefit in 
animal studies through decreases in reperfusion injury.  
2. Hyperbaric oxygen for stroke protocol background 
This chapter discribes the protocol which we propose ulitmitaly leading to a multicenter 
trial, as follows.  
The purpose of this study is to determine the safety of hyperbaric oxygen therapy of acute 
ischemic stroke at a dose of 2.4ATA for 90 minutes administered in the first 12 hours of 
symptoms. The data obtained will be used to determine safety and to estimate effect size in 
order to plan a larger, adequately powered, multicenter trial.  
Presently, in the US, tPA is the only FDA approved therapy for treatment of acute ischemic 
stroke (AIS). Unfortunately, only around 3-5% of patients with stroke receive tPA therapy 
due to the strict time limitations and the high risk of bleeding associated with its use. 
Therefore, other modalities of treatment for acute ischemic stroke need to be investigated. 
Animal studies have suggested that administration of pure oxygen at high pressure can be 
protective against the effects of cerebral ischemia. Some small uncontrolled studies in 
humans have shown benefit of HBO. However, no study has tested HBO in stroke at a time 
and a dose which, based on animal studies, could be expected to be effective. 
HBO therapy of cerebral ischemia has been shown to be effective in numerous animal models 
of AIS (1). Animals treated with HBO after either temporary (2, 3, 4, 5, 6, 7, 8, 9, 10) or 
permanent (9, 10) cerebral arterial occlusion showed decreased infarct size versus controls. 
Improved survival, function and behavior in HBO treated animals were also reported (2, 3, 5, 
6, 9, 10, 11, 13, 14, 15, 16, 17, 18, 19). Several of the studies used a model involving the nearly 
immediate institution of HBO, starting treatment immediately (2, 9, 13, 20) or within minutes 
(8, 11, 12, 14) of ischemia. In models more consistent with conditions in a clinical setting, 
however, HBO delayed until several hours after the beginning of ischemia was also been 
shown to be effective. (3, 4, 7, 8, 10, 15) There may, though, be an early window of opportunity 
after ischemia for HBO to be effective. One study found that treatment after 1 or 3 hours of 
ischemia decreased infarct size and improved outcome behaviorally, whereas, treatment after 
4 hours had no effect on infarct size. (3) A more recent study, however, showed that HBO 
treatments initiated up to 24 hours after transient cerebral ischemia in rats resulted in 
decreased infarct size and neurologic deficits at 4 weeks (10). 
Human trials of HBO for AIS have been less conclusive. Most of the early trials reported a 
benefit from treatment of ischemic stroke patients with HBO. (21, 22, 23, 24, 25) These trials, 
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however, were for the most part, uncontrolled, and utilized greatly disparate criteria for 
inclusion as well as for evaluation of improvement. Of the three small recent randomized 
trials of HBO in AIS (26, 27, 28), no significant difference was seen between treatment and 
sham groups. Significantly, however, treatments were not limited to the hyperacute stage, as 
patients were enrolled up to 24 hours after symptom onset in 2 studies, and up to 2 weeks in 
the third. Also, in two of the studies, patients receiving sham treatment were given either 
hyperbaric air, or 100% O2 at slightly increased pressure, neither of which is known to be 
clinically insignificant. Further, these studies used a lower dose of HBO than has been 
shown effective in animal studies, as well as in human clinical use for other approved 
indications (wound healing, CO poisoning, etc.)  
All but one of the studies evaluating HBO therapy of ischemic stroke have used a dose of 1.5 
ATA. This was selected based upon concerns for increased risk of oxidative stress with 
higher doses suggested in a single study from 1977 (29). This study was limited, however, 
by inclusion of only 7 ischemic stroke patients (the rest had traumatic brain injury) and the 
administration of HBO several days after the cerebral insult. Despite concerns for increased 
oxidative stress, the patients who received the higher doses of HBO did not have seizures or 
worsening of neurologic deficits. 
There is a theoretical concern that hyperbaric treatment at a higher dose could cause 
oxidative stress through free radical damage leading to an increase in neuronal loss and 
thus a worse clinical outcome. Some animal studies have shown increases in lipid 
peroxidation (52), a marker of free radical damage, but most have not (12, 53-55). The single 
study which assessed the use of HBO at 2.5 ATA in acute stroke did raise concerns of 
worsened stroke outcome at the higher dose, but was limited by several factors (28). First, 
most of the patients were treated after 12 hours. Second, the control group was subjected to 
100% O2 at 1.14 ATA, which is not standard care. Third, there was no cut-off for stroke 
severity, such that very mild strokes were included, making evaluation of the effect of HBO 
difficult. Also, the differences seen were not statistically significant. 
The selection of the dose for this study is based on several facts. First, HBO is approved for 
use by the FDA at a dose of 2.4 ATA for 90 minutes for treatment of numerous conditions 
and is well tolerated (30). Despite the above stated safety concerns, patients with arterial gas 
embolism and decompression illness, both of which commonly cause ischemia of the central 
nervous system, are treated with even higher doses of HBO with good efficacy and 
acceptable safety levels (31, 32). This cannot, however, be directly compared to ischemic 
stroke as the pathological mechanism of ischemia is different, and as such, a study is 
warranted. Second, this dose is more consistent with animal studies which have shown 
efficacy (see above). 
The rationale for the use of HBO in cerebral ischemia centers upon increasing oxygenation 
to an ischemic penumbra and thus reducing the subsequent effects of hypoxia. Additionally, 
there may be other effects of HBO contributing to improved outcome after cerebral 
ischemia. Decrease in cerebral blood flow caused by oxygen induced vasoconstriction, has 
been shown in humans (35) as well as animals (5, 36) treated with HBO, and may produce a 
decrease in cerebral edema. Also, HBO may have benefit in the treatment of stroke by 
exerting an indirect neuroprotective effect. Decreased neuronal shrinkage and edema as 
well as decreased necrotic damage have been described histologically in animals treated 
with HBO after ischemia. (13, 19, 20, 37) Additionally, and perhaps more importantly, far 
fewer neurons show evidence of having undergone subsequent apoptosis after ischemia in 
animals treated with HBO. (15, 37, 38) HBO exposures in the first few minutes or hours after 
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ischemia must, therefore, effect a lasting physiologic change which interrupts the 
subsequent cell death cascade. 
It is felt that this effect may be mediated through inhibiting the inflammatory response to 
ischemia. Neutrophil accumulation and adhesion have been identified in ischemic brain 
tissue (39) and are correlated with poor clinical outcome (40, 41). Elevated serum levels of 
selectin and immunoglobulin-type adhesion molecules have been described after acute 
stroke (42, 43, 44). In other studies, elevated serum levels of ICAM-1 seen at 12 and 24 hours 
after symptom onset were shown in humans to be directly related to infarct size on diffusion 
weighted imaging (45). In the same group of studies matrix mettaloproteinases were also 
shown to be elevated in ischemia and presentation levels of MMP-9 were correlated with 
eventual infarct size (45). 
Previous studies have shown that administration of antibodies to ICAM-1 after transient 
cerebral ischemia in animals decreased leukocyte adhesion and limited infarct size as well as the 
number of apoptotic cells (46, 47, 48) suggesting there is a neuroprotective effect of decreasing 
ICAM-1 activity after reperfusion. Hyperbaric oxygen therapy may exert its antiapoptotic 
effects through this pathway, since decreased leukocyte adherence and neutrophil 
accumulation were seen after cerebral ischemia in HBO treated animals (5, 9). ICAM-1 levels 
have also been shown to be decreased in ischemic tissues in HBO treated animals (49), as well 
as in human tissue cultures (50) Interestingly, this effect was not seen in non-reperfused tissue 
(22, 47). Also, in healthy human volunteers, HBO treatment caused reductions in leukocyte 
adherence that was seen at 2.8 and 3.0 ATA but not at 1.0 or 2.0 ATA (51). 
The outcomes scales selected for the study includes the NIH stroke scale (NIHSS), the 
modified Rankin scale (mRS), the Barthel index, and the Glasgow Outcome scale. These 
have been used and validated in numerous stroke studies. As they are non-linear scales, 
they have been utilized for binary outcomes, good versus poor. Good outcome designations 
are usually understood to be NIHSS ≤ 1, mRS ≤ 1, Barthel 95-100, Glasgow Outcome scale= 
5. (33, 34) 
3. Hypothesis and objectives 
Hyperbaric oxygen therapy administered within twelve hours of symptom onset to patients 
with acute ischemic stroke at a dose of 2.4 ATA for 90 minutes is safe.  
Specific Aim 1: Safety 
We will determine whether patients presenting with acute ischemic stroke with a National 
Institute of Health Stroke Scale score of ≥4 given one treatment of hyperbaric oxygen at  
2.4 ATA for 90 minutes initiated within 12 hours of symptom onset do not have a 
significantly higher rate of adverse events, or a singificantly increased infarct size by MRI. 
Specific Aim 2: Pilot data for a larger study 
This study will provide pilot data to be used to estimate effect size of the use of HBO on 
functional outcome of ischemic stroke as stated above in order to determine sample size to 
adequately power a larger multicenter study to determine efficacy of the treatment. 
Specific Aim 3: Pilot data on mechanism of HBO  
3a. Perfusion:  
We will gather pilot data on the effect of treatment with HBO as described above on 
perfusion of the ischemic territory evaluated by pre- and post-treatment perfusion MRI 
scanning of the brain (in the first 20 patients). This will be used to gain insight into whether 
a protective effect of HBO is mediated through altered perfusion to the ischemic penumbra, 
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or if, as is expected, perfusion is not directly affected, but poorly perfused brain territory is 
protected by other mechanisms. 
3b. Leukocyte adhesion: 
We will test the hypothesis that the mechanism of neuroprotection provided by hyperbaric 
oxygen therapy exerts itself through changes in leukocyte adhesion. Using MMP-9 levels at 
presentation, known to be correlated with eventual infarct size, as a standard for stroke 
severity, we will determine whether the normally exhibited increase in serum levels of 
ICAM, VCAM and SELAM after onset of acute ischemic stroke, also correlated with infarct 
size, is attenuated in patients receiving HBO therapy as described above, and if the decrease 
in leukocyte adhesion factors correlates with decreased infarct size and improved 
neurologic outcome. 
This is how we determined the number of participants necessary to conduct the study: 
1. To evaluate efficacy, the first 10 subjects in each group – HBO and non-HBO – will have 
in addition to their NIHSS, Barthel index and Rankin scale score, an MRI with diffusion 
and perfusion weighted imaging, which will be performed pre and post treatment (for 
the first 20 patients and 72 hours post enrollment for the control group). If there is no 
differential effect between the controls and the HBO on outcome, the study will be 
terminated for lack of efficacy. 
2. To evaluate safety, 36 subjects in each of the HBO and non-HBO stroke treatments 
would allow a difference of 20% in aspiration pneumonia Adverse Events to be 
detected with a power of 80% and a type I (alpha) error of 5%. This would also allow 
detection of a 20% increase in the rate of post-treatment seizures. 
The acute stroke team will make first contact when they are consulted for patients with 
acute ischemic stroke. Patients will be recruited from all emergency room and inpatient 
consults for acute stroke called to the stroke team. Women and minorities will be included 
as they present.  
Patients and/or involved family members will be presented with the study and the 
informed consent will be obtained after all questions/concerns are addressed completely. If 
the patient is unable to give informed consent themselves, then the LAR will give informed 
consent on their behalf. If the patient does not have a LAR (Living adult relitive), then we 
will solicit consent from a next of kin (in the following order): the spouse, adult child, 
parent, adult sibling, grandparent, or adult grandchild. If none of these options are available 
then we will be unable to consent the patient and they will not be considered for enrollment 
in the study. If patient's become able to give consent during the study period they will be 
reconsented at that time. 
Potential subjects and their families will be told that this is an emergency treatment study. 
We will explain that time is of the essence and that if they feel they are unable to make an 
informed decision in a timely fashion (approx. 20 minutes), they will be unable to 
participate in the study. We had several people with no medical background who are not 
involved with the study read the consent form and on average it took them about 20 
minutes to read and understand the consent and fill out the consent questionnaire. 
The consent questionnaire is used to evaluate the consent process and document the 
understanding of the patient and/or LAR of his/her obligations as a patient and the 
obligation of the PI. If the patient or LAR failed to answer more than 50% of the questions 
we will offer them the opportunity to rereview the consent forms. If they continue lack of 
understanding of the research study we will no longer consider them for participation. 
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Exclusion criteria: 
1. Neuroimaging evidence of ICH, intraventricular or subarachnoid blood, tumor, 
encephalitis or diagnosis other than stroke. 
2. Posterior circulation infarction. 
3. Active pulmonary disease, pneumothorax, intubation or possible necessity for 
intubation. ABG findings of pH < 7.32 or pCO2 >49. 
4. Active cardiac disease. 
5. Decreased level of consciousness (score > 0 on NIHSS item #1a). 
6. Inability to lie flat. 
7. Claustrophobia. 
8. Life expectancy less than 6 months. 
9. Pregnancy or breast feeding. 
10. Treatment with any other experimental stroke therapy since symptom onset. 
11. Patients requiring continuous IV treatment for elevated or depressed blood pressure. 
12. Inability to undergo MRI (pacemaker, AICD, etc.) 
13. History of seizure. 
14. Diabetic patients with a blood glucose <110 
15. A GFR blood test resulting in a value of <30 because then the patient would be unable 
to undergo MRI with contrast. 
16. History of inner or middle ear surgery (other than tube placement) 
17. History of pneumothorax. 
18. History of exposure to Bleomycin. 
19. Presently taking steroids. 
20. Presently taking Doxorubicin, cis-platinum or disulfiram. 
The target enrollment will be 72 patients. Subjects arriving in the emergency department 
with a presumptive diagnosis of acute stroke will be evaluated by the on-call neurologist. If 
the time since symptom onset is less than 12 hours and the subject has no known exclusion 
criteria, a certified examiner will evaluate them using the NIHSS. 
Subjects with at least a score of 4 on the NIHSS who are determined to have anterior 
circulation ischemia as determined by the clinical judgment of the examiner will be enrolled. 
The NIHSS will be conducted by a study team member, all of whom are NIHSS certified by 
the American Heart Association and the National Stroke Association. If a subject is 
determined to have a NIHSS of less than 4, they will not be considered eligible for the study. 
Also, if a patient is non-responsive when exmained, they will also be excluded from the 
study. A copy of the NIHSS is included in the source documents which are attached to 
section 52 of the study smartform. A pregnancy test will be performed on all women of 
child-bearing age who have a uterus and ovaries. Premorbid mRS score will be discerned 
through discussion with the patient or family/friends. If this information if not available in 
time for randomization, the subject will be excluded. If treatment cannot be started within 
12 hours from symptom onset, the subject is excluded. Patients deemed candidates for 
thrombolytic therapy will be treated accordingly and if the patient is randomized to 
treatment, the HBO will not begin until the tPA infusion has ended. 
A noncontrast head CT is done routinely on all patients presenting to the emergency 
department with acute stroke. This CT scan will be reviewed for evidence of ICH or other 
exclusionary pathology prior to randomization. 
As part of the normal standard of care for these patients, anyone presenting with a possible 
stroke has an acute stroke panel blood work-up done. A creatinine test is done as part of this 
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panel. Patient's need to have normal kidney functions in order to have gadolinium given 
with their MRI. If a patient has a GFR of < 30, then they will be exlcuded from the study. 
This would indicate abnormal kidney functions and they would be unable to undergo MRI 
with contrast. 
In all patients enrolled, NIHSS assessment will be repeated at 7 days or at discharge from 
the hospital, whichever is first. Rankin scale, Barthel index, and Glasgow outcome scale will 
be assessed at the same time. Subjects will have a follow-up clinic visit at 90 days with 
repeat NIHSS testing as well as mRS score, Barthel index, and Glasgow outcome scale 
assessment. (see Appendix A) 
If the subject agrees to participate, an arterial blood gas will be drawn for evaluation. 
Patients exhibiting blood gas abnormalities consistent with underlying pulmonary disease 
(pH <7.32 or >7.48 or pCO2 > 49) will be excluded. Eligible patients will be randomized in 
equal numbers to receive HBO treatment or standard of care treatment. 
If no exclusions exist, the subjects randomized to HBO therapy will receive one treatment of 
100% O2 at 2.4ATA for 90 minutes in a monoplace hyperbaric chamber. 
Prior to treatment an MRI of the brain with diffusion weighted imaging will be performed. 
Infarct size will be estimated by selecting the image with the largest area of restricted 
diffusion. This will be measured by length x width x slice thickness to estimate infarct 
volume in that slice as an estimate of infarct size. If more than one area of infarction exists, 
they will be evaluated separately and added together. The first twenty patients randomized 
will undergo further testing. In those patients, 10 HBO, 10 control, MRI with diffusion and 
perfusion weighted imaging will be performed within 72 hours following treatment or 
randomization for the control patients. A liquid containing gadolinium contrast agent will 
be innjected into a vien prior to the MRI scan. This agent increases the ability of the MRI 
scan to show abnormal tissues in the brain or elsewhere in the body. 
Blood will also be drawn at randomization and at 12 and 24 hours from stroke onset (if 
different from randomization). These will undergo enzyme-linked immunosorbent assays 
on plasma for MMP-9 and serum for ICAM-1, VCAM-1, and sELAM-1. Additionally, PFA-
100 platelet function tests will be run on blood drawn at enrollment and 24 hours. 
Our primary outcomes will be rates of adverse events and infarct size on MRI diffusion 
weighted imaging (DWI). Adverse events will include pneumonia, seizures, and infarct 
increase. An infarct increase will be defined as an increase in the area of restricted diffusion on 
DWI over pretreatment baseline of greater than 10% for patients with no diffusion-perfusion 
mismatch, or a final DWI lesion size which is greater than 10% larger than the baseline 
perfusion deficit for patients with a perfusion-diffusion mismatch. The rate of adverse events 
will be compared between treatment and control groups. If the rate of AEs is not statistically 
significantly larger in the treatment group, the treatment will be considered safe. 
Secondary outcomes will include modified Rankin scale score, NIHSS score, Barthel index 
score, length of hospital stay, intracerebral hemorrhage and symptomatic intracerebral 
hemorrhage rates and discharge location. Patients will be categorized as having a good 
outcome (NIHSS 0 or 1, Rankin 0 or 1) or not. The number of patients in treament and 
control groups achieving a good outcome will be compared. If there is a significant increase 
in good outcome in the treatment group, the treatment will be considered effective. 
Data collected specifically for research purposes will include: NIHSS scores at 7 days or 
discharge, and at 30 days, as well as mRS scores, Barthel index, and Glasgow outcome 
scores at 7 and 30 days. 
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These are the risks we will explain to patients: 
Common: 
1. Claustrophobia during HBO treatment or MRI (reversible, treat by terminating HBO  
or MRI) 
2. Ear pain during HBO treatment (reversible, treat by terminating HBO) 
Uncommon: 
1. Hematoma or bleeding from blood draws (reversible or treatable with transfusion) 
2. Infection from blood draws (treatable with antibiotics) 
3. Increased likelihood of aspiration pneumonia (treatable with antibiotics) 
Very uncommon: 
1. Seizure from HBO (reversible, treat by terminating HBO) 
2. Barotrauma from HBO including pneumothorax, ruptured eardrum, (usually 
reversible/treatable) 
3. Breach of confidentiality/loss of privacy 
4. Allergic reaction to MRI contast medium (treatable with antihistamines, epinephrine). 
Side effects, such as mild headache, nausea and local burning at the IV site can occur. 
Patients are occasionally allergic to gadolinium contrast resulting most commonly in 
hives and itchy eyes, and in very rare cases, a bee-sting type of severe allergic reaction 
(anaphylactic shock). Use of a gadolinium contrast agent may be linked to a rare but 
sometimes fatal condition (nephrogenic systemic fibrosis or NSF) in people with severe 
chronic kidney disease or acute kidney problems. Therefore, before you are given a 
contrast agent for MRI, your risk factors for kidney disease will be reviewed and a 
blood test for kidney function will be done to exclude severe kidney disease 
Patients will be screened by a physician with specialized training in hyperbaric medicine to 
exclude patients at higher risk of adverse affects from HBO. Trained technicians will 
monitor treatment under the supervision of this physician to assess patients during 
treatment and terminate treatment if necessary. Patients will be monitored through constant 
verbal and visual contact and if deemed necessary, through continuous pulse oximetry and 
blood pressure measurements. Blood draws will be performed under usual precautions 
against infection and bleeding. 
All patient data will have most identifiers removed (except age, which may include those 
>89 years old) and will be stored on a password-protected computer database. Additionally 
a checklist for side effects and their severity will be filled out at completion of the HBO 
treatment and at discharge or 7 days whichever is earlier. In the case of ear pain which does 
not resolve after return to normal pressure, ENT will be consulted for evaluation and 
quantification of any damage using the Teed Scale for quantification. 
Patients will be monitored clinically while receiving hyperbaric treatment by the technician 
and the physician. Patients will be monitored by constant visual and verbal contact and 
when deemed necessary by the treating physician, by continuous pulse oximetry and blood 
pressure monitor. Patients will be monitored while inpatient by one of the study physicians 
or nurses for AEs or SAEs. AEs or SAEs occurring after discharge will be assessed at the 
follow-up visit. Any adverse events or serious adverse events will be reported to the PI 
immediately. 
The potential benefit to the subject is improved outcome in terms of neurologic function by 
limiting the damage to the brain from ischemia. Other patients and society could benefit by 
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the development of an additional therapy to limit brain damage from acute ischemic stroke, 
particularly in patients who are not thrombolytic candidates. Data will be kept on a 
password-protected database. Only participating study team members will have access to 
the database. Specimins of serum and plasma will be kept in a locked freezer prior to 
analysis. Only study team members will have access to the freezer. 
4. Conclusions 
Hyperbaric oxygen (HBO) therapy of cerebral ischemia has been evaluated in a number of 
human and animal studies; however, there is presently no consensus on its efficacy.  We 
performed a systematic review of the literature searching Medline database from 1966-2005 
using the terms: hyperbaric, hyperbaric oxygenation, cerebrovascular accident, stroke, 
ischemia, and infarction. We identified 603 articles and selected 89 as relevant.  Animal 
studies of HBO have shown promise by reducing infarct size and improving neurologic 
outcome. Early reports in humans also suggested benefit in stroke patients treated with 
HBO. Recent randomized, controlled human studies, however, have not shown benefit. All 
but one of the studies evaluating HBO therapy of ischemic stroke have used a dose of 1.5 
ATA, based upon concerns for increased risk of oxidative stress with higher doses suggested 
in a single study from 1977. Despite concerns for increased oxidative stress, the patients who 
received the higher doses of HBO did not have seizures or worsening of neurologic deficits. 
The single study which assessed the use of HBO at 2.5 ATA in acute stroke did raise 
concerns of worsened stroke outcome at the higher dose, but was limited by several factors. 
First, most patients were treated after 12 hours. Second, the control group was subjected to 
100% O2 at 1.14 ATA, which is not standard care. Third, there was no cut-off for stroke 
severity, such that very mild strokes were included, making evaluation of the effect of HBO 
difficult. Important differences between animal and human studies suggest HBO might be 
more effective in stroke within the first few hours and at a pressure of 2 to 3 ATA. Therefore, 
clinical trials of HBO in acute ischemic stroke should be designed to evaluate treatment 
administered earlier and in higher doses to more clearly address its efficacy. We propose 
such a clinical trial, in this chapter. 
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